# The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy

> **NCT02604615** · PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital of Henan University of Science and Technology** · enrollment: 60 (estimated)

## Conditions studied

- Stage III Esophageal Squamous Cell Carcinoma
- Esophageal Neoplasms

## Interventions

- **DRUG:** Capecitabine(Aibin)
- **DRUG:** Oxaliplatin(Aiheng)
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02604615
- **Lead sponsor:** The First Affiliated Hospital of Henan University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10
- **Primary completion:** 2017-12
- **Final completion:** 2020-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-07-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02604615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02604615, "The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02604615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*